SELLAS Life Sciences Group Inc
Research SELLAS Life Sciences Group Inc (SLS) on Bullrun: market cap USD 2.62B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.62B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 8.41M
- Free cash flow-USD 8.85M
Valuation Snapshot
latest market cap is USD 2.62B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.86M | -USD 28.39M | n/a | -0.25 | USD 71.79M | USD 1.00M | USD 70.87M |
| FY2024 | USD 0 | -USD 30.88M | -USD 35.40M | n/a | -0.5 | USD 13.89M | USD 1.00M | USD 9.47M |
| FY2023 | USD 0 | -USD 37.34M | n/a | n/a | -1.34 | USD 2.53M | USD 906.00K | -USD 7.98M |
| FY2022 | USD 1.00M | -USD 41.30M | n/a | 90.0% | -2.13 | USD 17.13M | USD 1.12M | USD 4.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.62B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 577.20M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 76.94M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 33.99M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 48.59M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 87.90M | n/a | n/a | n/a |
About SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is SELLAS Life Sciences Group Inc's market cap?
SELLAS Life Sciences Group Inc's market capitalization is USD 2.62B.
What does SELLAS Life Sciences Group Inc do?
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.